196 related articles for article (PubMed ID: 36200429)
1. Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study.
Guo Z; Ding Y; Wang M; Liu J; Zhai Q; Du Q
J Clin Pharm Ther; 2022 Nov; 47(11):1837-1844. PubMed ID: 36200429
[TBL] [Abstract][Full Text] [Related]
2. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
[No Abstract] [Full Text] [Related]
3. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
[TBL] [Abstract][Full Text] [Related]
4. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.
Ma P; Tian H; Shi Q; Liu R; Zhang Y; Qi X; Chen Y
Expert Opin Drug Saf; 2023; 22(8):685-696. PubMed ID: 37068935
[TBL] [Abstract][Full Text] [Related]
5. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
Tang L; Sun C; Liu W; Wu H; Ding C
Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
[No Abstract] [Full Text] [Related]
6. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database.
Ma Z; Zhang Y; Zhu M; Feng L; Zhang Y; An Z
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1351-1361. PubMed ID: 36111954
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
10. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
[TBL] [Abstract][Full Text] [Related]
11. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
12. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
[TBL] [Abstract][Full Text] [Related]
13. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
Abuhelwa Z; Alloghbi A; Alqahtani A; Nagasaka M
Drugs; 2022 Jun; 82(9):979-987. PubMed ID: 35759121
[TBL] [Abstract][Full Text] [Related]
15. The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single-arm meta-analysis.
Li R; Hua M; Li J; Chen W; Xu L; Meng H; Zhang Z; Liu Q; Cui Y; Xiang Q
Cancer; 2024 May; ():. PubMed ID: 38703012
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
18. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
19. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
20. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Swain SM; Nishino M; Lancaster LH; Li BT; Nicholson AG; Bartholmai BJ; Naidoo J; Schumacher-Wulf E; Shitara K; Tsurutani J; Conte P; Kato T; Andre F; Powell CA
Cancer Treat Rev; 2022 May; 106():102378. PubMed ID: 35430509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
